Safety-Driven Ocrelizumab Discontinuation Vs Continuation: Comparative Insights From MSBase

D'Amico, EmanueleZanghi, AuroraSpelman, TimKermode, Allan G.Pedrini, MarzenaCarroll, WilliamGerlach, Oliver2025-12-302025-12-3020251352-45851477-0970https://hdl.handle.net/20.500.14365/8568eninfo:eu-repo/semantics/closedAccessSafety-Driven Ocrelizumab Discontinuation Vs Continuation: Comparative Insights From MSBaseConference Object